Cerenome/$CNSY
1D1W1MYTD1Y5YMAX
About Cerenome
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
- Ticker
- $CNSY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 28
- Headquarters
- Houston, United States
- Website
- cerenome.com
Cerenome Metrics
BasicAdvanced
$23M
-
-$4.37
1.42
-
Price and volume
Market cap
$23M
Beta
1.42
52-week high
$8.00
52-week low
$2.90
Average daily volume
75K
Financial strength
Current ratio
1.374
Quick ratio
1.232
Total debt to equity
0.805
Interest coverage (TTM)
-1,200.00%
Profitability
EBITDA (TTM)
-25.945
Gross margin (TTM)
-197.57%
Net profit margin (TTM)
-620.70%
Operating margin (TTM)
-628.12%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
-135.36%
Return on equity (TTM)
-614.05%
Valuation
Price to revenue (TTM)
4.362
Price to book
4.08
Price to tangible book (TTM)
4.62
Price to free cash flow (TTM)
-0.778
Free cash flow yield (TTM)
-128.46%
Free cash flow per share (TTM)
-3.918
Growth
Revenue change (TTM)
-20.95%
Earnings per share change (TTM)
-85.44%
3-year revenue growth (CAGR)
17.60%
10-year revenue growth (CAGR)
-9.65%
3-year earnings per share growth (CAGR)
-71.69%
Cerenome News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.